Hopes were high. In retrospect, perhaps too high.
On Monday, Novo Nordisk announced that two large studies failed to find any effect of the drug semaglutide on cognition and functioning i
Continue Reading on New York Times
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.